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ABSTRACT
Cataplexy is frequently misdiagnosed as pseudoseizures. This case study about
a young patient shows the necessary steps needed to accurately diagnose and
treat cataplexy as well as understand the differences between narcolepsy Type I
and Type II.

Author affiliations are
listed at the end of this
article.
Correspondence to:

Sammar Atassi, MD
West Virginia University
School of Medicine
wvmedical@yahoo.com

KEYWORDS

Cataplexy, Narcolepsy, Pseudoseizure

HISTORY
The patient is a seventeen-year-old female with a past
medical history of depression. She was referred to the
sleep center by a neurologist for seizures. She has also
been followed by her pediatrician for the past two
years where she was first given a diagnosis of seizure
versus pseudoseizure. The patient’s symptoms started
around age fifteen when her family noticed a pattern
of her falling to the ground frequently during highly
emotional situations.
CLINICAL FINDINGS
A physical exam of the patient revealed a morbidly
obese female with a BMI of 54, blood pressure of
146/90, pulse of 93, height of 5 foot 4 inches, and
weight of 314 pounds. Oxygen saturation was 100%
on room air. Otherwise, her physical exam was
unremarkable except for a Mehta Patti score of 2. The
Epworth sleepiness score was 21. Her medications
included: Wellbutrin SR 100 mg once a day, Yasmin 28
once a day, and Synthroid 50 mcg once a day. Other
laboratory data were unremarkable.

MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

Her family physician suspected a seizure disorder
and ordered an electroencephalogram (EEG),
which was negative. She was then diagnosed with
pseudoseizure due to her significant anxiety and
ongoing depression. She continued taking several
antidepressants (Venlafaxine XR and Sertraline),
which failed to alleviate her symptoms.
She was next evaluated by the neurologist. The
patient was losing muscle tone in her legs when
laughing, crying, or otherwise showing emotions.
She denied jerking movements in the upper or lower
extremities, and there was no postictal confusion.
It was obvious that the patient was also extremely
sleepy; her family attributed her sleepiness and
fatigue to depression. She was falling asleep as a
passenger in the car and at school during class.
When evaluated at the sleep lab, the patient was
noted to have poor sleep hygiene. She went to
bed around midnight and awoke around 6 AM, but
she took frequent naps during the day. She denied
restless legs, though sleep during the night was
restless. She did not feel refreshed upon awakening in
the morning. Naps of two to three hours at least once
a day, however, were very refreshing. She denied
sleep paralysis, but she reported vivid dreams. She
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described her falling episodes as “knee-buckling” with
a total loss of muscle tone in the lower extremities
only in emotional situations, such as when feeling
nervous, crying, or laughing. These falling episodes
were not associated with a loss of consciousness.
She denied hallucinations and reported occasional
snoring. She was depressed but denied suicidal
ideation; she felt embarrassed when these falling
episodes happened. The culmination of these
symptoms was highly suspicious of cataplexy.
INVESTIGATIVE FINDINGS
Narcolepsy was suspected based on the DSM-V
criteria and the presence of cataplexy. To rule out
obstructive sleep apnea based on the extreme
obesity and presence of snoring, a sleep study
was performed after cessation of Wellbutrin for
two weeks. The polysomnogram (PSG) revealed a
total sleep time of 480 minutes with a somewhat
decreased sleep efficiency of 80% with REM latency
of 61 minutes. Her AHI was 2.9 and snoring was mild
with no significant leg movements. The hypnogram
revealed sleep fragmentation and frequent arousals
with poor sleep efficiency (Figure 1).

Additional testing involved a multiple sleep latency
test (MSLT). In this diagnostic test for narcolepsy, the
patient is given the chance to take five 20-minute
naps. This test is used to measure the time to reach
the sleep stage for each nap (sleep latency), and if
REM sleep is reached within 15 minutes of sleep,
then it is considered a sleep-onset REM (SOREM).
Mean sleep latency was reduced to 1 minute and
the patient went into REM sleep in 3 out of the 5
naps (Figure 2). Furthermore, the patient’s drug
screen was negative; a diagnosis of narcolepsy was
established.
The patient was treated with Adderall XR 10 mg
daily, which was increased to 20 mg after 1 week
due to ineffectiveness. Her hypersomnia significantly
improved after the increased dosage of Adderall
XR and her Epworth Score decreased to 9. She
continued to experience cataplexy symptoms,
and thus, Effexor X 37.5mg was added at bedtime.
With the addition of this medication, the cataplexy
symptoms completely resolved, and school
performance significantly improved. Her threemonth follow-up appointment was remarkable for
complete resolution of her cataplexy and daytime
sleepiness; her self-reported depression symptoms
also significantly improved.

FIGURE 1. The hypnogram shows the sleep stages, respiratory events, oxygen saturation, sleep
waves, snoring, and leg events. The sleep stages in blue (N2), green (N3), and red (REM) are interrupted by frequent arousals in black causing frequent sleep fragmentation.
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FIGURE 2. This MSLT summary shows sleep latencies and REM latencies and confirms the presence of 3 REM sleep onset events (SOREM).
DISCUSSION: THE SIGNIFICANCE OF PROPER
DIAGNOSIS OF CATAPLEXY
Narcolepsy is a common sleep disorder associated
with extreme daytime sleepiness that affects 1
in 2,000 people.1,2 Narcolepsy commonly starts
in childhood, although diagnosis is commonly
missed and delayed by at least ten years. Excessive
daytime sleepiness is always present, but the other
symptoms, including sleep paralysis, hallucinations,
cataplexy, and sleep paralysis, are not always
present. Cataplexy is found in 60-70% of patients
with narcolepsy. 2,3 Cataplexy causes muscle
weakness, which occurs during REM sleep, during
the waking hours, and in association with a form of
emotional expression. This sudden loss of muscle
tone may also initially develop as experiencing slight
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jaw drop to slight or significant weakness in the arms
and legs where the person can no longer stand.
There are two types of narcolepsy. Narcolepsy
type I is defined as narcolepsy with cataplexy, and
Narcolepsy type II is defined as narcolepsy without
cataplexy.2,4 The etiology of narcolepsy is not well
known, but nearly all patients with Narcolepsy type
I have low or absent hypocretin, which is a hormone
responsible for wakefulness and regulating REM
sleep. An autoimmune etiology has been suggested,
even though the disease is not genetic, but it does
cluster in families.
The diagnosis of narcolepsy is based on the results
of a PSG and a multiple sleep latency test (MSLT).
A negative PSG rules out sleep apnea. To confirm a
diagnosis of narcolepsy, the MSLT, which assesses
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the daytime sleepiness by allowing patients to take
five naps the following day, shows short (<8 min)
sleep latency and occurrence of REM within 15 min
of sleep onset in at least two of the five naps during
the MSLT. If the patient experiences REM sleep onset
within 15 minutes from sleep onset during the PSG,
this episode may be counted as one of the MSLT
SOREM episodes. Once two episodes of SOREM are
confirmed, the patient is diagnosed with narcolepsy.
Cataplexy is confirmed by witnessed episodes of the
patient and family. Measuring hypocretin levels in
cerebral spinal fluid is confirmatory diagnostic, but
not commonly performed.
Genetic tests are still in the early stages. We know
that patients who have the genetic marker HLA
–DQB1*06:02 are at increased risk for narcolepsy
and especially Narcolepsy type I.4 However, testing
for this genetic marker is not proven yet to help
establish a narcolepsy diagnosis.
Treatment options include stimulants such as
modafinil and amphetamines.4,5 Newly approved
stimulants in 2019, including a histamine-3 receptor
agonist, Pitolisant, and a dopamine/norepinephrine
reuptake inhibitor Solriamfetol, are also effective
treatment options. Sodium oxybate, which is
usually administered twice a night, is approved
for the treatment of narcolepsy and cataplexy.
In addition, antidepressants such as selective
serotonin reuptake inhibitors (SSRIs) are commonly
administered to treat the cataplexy symptoms. Due
to the delay in the narcolepsy diagnosis, patients
with narcolepsy frequently experience depression.
Therefore, addressing that issue is essential to
improve the quality of life. It is not uncommon for
cataplexy to be confused with conversion disorder,
due to the association of cataplexy with emotional
situations. Finally, patients must learn that lifestyle
modifications are important such as taking daily
naps.
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